
Akso Health Group: stock overview
Price
$1.24
November 20, 2026Market cap $896M
What Ploutos Investor adds for Akso Health
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from FY2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Akso Health had revenue of $14M in the fiscal year to March 31, 2026 and a net loss of $19M. Revenue grew by 51.1% a year on average over the last 5 years. It holds more cash than debt, by $170.6K. It pays no dividend.
From its SEC filings (latest fiscal year to March 31, 2026) and the price of November 20, 2026.
Its SEC filings- Market cap
- $896M
- 723M shares
- P/E
- –
- Revenue, fiscal year
- $14M
- +51.1% a year over 5 years
- Net margin
- -135.0%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+139.4% a year over 2 years
Fiscal years in figures
AHG's revenue, profit, cash flow and dividend with each year-end price, from FY2017 to FY2023, 7 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $651M
- $896M
- Enterprise value
- $896M
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- 64.8
- P/B 3-year median: 3.3
- 5.0
- FCF yield
- –
- Earnings yield 3-year median: -18.1%
- –
Profitability
- Gross margin
- -0.1%
- Operating margin
- -149.7%
- Net margin 3-year median: -391.8%
- -135.0%
- ROIC
- -9.0%
- ROIC, 5-year average
- -52.3%
- ROE, fiscal year
- -10.3%
Growth
- Revenue, yearly change
- -6.4%
- EPS, yearly change
- –
- FCF, yearly change
- -1,350.9%
- Revenue, average a year
- +51.1%
The yearly change compares FY2026 with FY2025.
Balance sheet
- Cash
- $170.6K
- Total debt
- $25.1K
- Of which operating leases
- $25.1K
- Net cash
- $170.6K
- Net debt / EBITDA
- –
- Interest cover
- –
- Current ratio
- –
Balance sheet of March 31, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +31.0%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Akso Health Group
- CIK
- 1702318
- Exchange
- NASDAQ
- Industry (SIC)
- 7389 · Services-Business Services, NEC
- Fiscal year ends
- March 31
- Latest annual report
- March 31, 2026
- Reporting currency
- USD
- Shares
- 723M
Other companies: Technology
The largest companies of the same sector, each with its own page.
- NVDANVIDIA+0,00%Compare with AHG
- AAPLApple+0,00%Compare with AHG
- MSFTMicrosoft+0,00%Compare with AHG
- AVGOBroadcom+0,00%Compare with AHG
- MUMicron Technology+0,00%Compare with AHG
- AMDAdvanced Micro Devices+0,00%Compare with AHG
- AMATApplied Materials+0,00%Compare with AHG
- INTCIntel+0,00%Compare with AHG
The full analysis
What do Akso Health's filings show?
These are Akso Health's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is AHG's market cap?
Akso Health Group's market cap is $896M, at a price of $1.24 on November 20, 2026 and 723M shares.
How much revenue does AHG have?
Akso Health had revenue of $14M in the fiscal year to March 31, 2026. Over the last 5 years it changed by +51.1% a year on average.
Does AHG pay a dividend?
No. Akso Health paid no regular dividend over the last 12 months.
Where do the figures come from?
From Akso Health Group's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.